Publications by authors named "Abdul Waris Durrani"
Article Synopsis
- - Major Depressive Disorder (MDD) is a common mood disorder affecting 264 million people globally, characterized by a persistent low mood and loss of interest lasting over two weeks, as defined by DSM-V criteria.
- - Zuranolone (SAGE-217) is being studied as a potential treatment for MDD, acting as a neuroactive steroid that enhances GABA receptor activity; it’s administered orally for two weeks and aims to improve depressive symptoms.
- - Early trials, including a phase II trial, show Zuranolone significantly reduced depression scores and was well tolerated, leading to further phase III trials to assess its safety and efficacy in treating MDD.